Entrada Therapeutics (TRDA) Short Interest Ratio & Short Volume → Elon’s New Device is About to Shock the World (From InvestorPlace) (Ad) Free TRDA Stock Alerts $14.99 +0.04 (+0.27%) (As of 05/17/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Entrada Therapeutics Short Interest DataCurrent Short Volume1,720,000 sharesPrevious Short Volume1,750,000 sharesChange Vs. Previous Month-1.71%Dollar Volume Sold Short$20.38 millionShort Interest Ratio / Days to Cover22.4Last Record DateApril 30, 2024Outstanding Shares33,760,000 sharesFloat Size18,020,000 sharesShort Percent of Float9.54%Today's Trading Volume104,887 sharesAverage Trading Volume65,052 sharesToday's Volume Vs. Average161% Short Selling Entrada Therapeutics ? Sign up to receive the latest short interest report for Entrada Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatTRDA Short Interest Over TimeTRDA Days to Cover Over TimeTRDA Percentage of Float Shorted Over Time Ad Paradigm PressDems have chosen Biden replacement?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election.See who it is HERE. Entrada Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/20241,720,000 shares $20.38 million -1.7%9.5%22.4 $11.85 4/15/20241,750,000 shares $22.56 million -1.1%9.7%23.2 $12.89 3/31/20241,770,000 shares $25.08 million -1.1%9.9%23.2 $14.17 3/15/20241,790,000 shares $22.88 million -1.1%10.1%22.9 $12.78 2/29/20241,810,000 shares $23.95 million No Change10.0%22 $13.23 2/15/20241,810,000 shares $27.19 million -1.1%10.0%20.6 $15.02 Get the Latest News and Ratings for TRDA and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Entrada Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/31/20241,830,000 shares $26.66 million +0.6%10.2%21.3 $14.57 1/15/20241,820,000 shares $29.79 million -1.1%10.1%21.8 $16.37 12/31/20231,840,000 shares $27.77 million +2.8%10.2%23.5 $15.09 12/15/20231,790,000 shares $24.93 million +0.6%10.0%25.1 $13.93 11/30/20231,780,000 shares $23.09 million +7.2%9.9%28.3 $12.97 11/15/20231,660,000 shares $27.12 million -3.5%9.3%30.4 $16.34 10/31/20231,720,000 shares $27.54 million +4.2%9.6%38.1 $16.01 10/15/20231,650,000 shares $21.62 million +5.1%9.3%37 $13.10 9/30/20231,570,000 shares $24.81 million +2.0%8.8%31.3 $15.80 9/15/20231,540,000 shares $25.61 million No Change8.6%26.1 $16.63 8/31/20231,540,000 shares $22.67 million -1.9%8.6%14.3 $14.72 8/15/20231,570,000 shares $25.10 million -1.3%8.8%14.2 $15.99 7/31/20231,590,000 shares $27.62 million -1.9%6.0%14.4 $17.37 7/15/20231,620,000 shares $26.45 million +1.3%6.1%14.6 $16.33 6/30/20231,600,000 shares $24.22 million +30.1%6.0%14.7 $15.14 6/15/20231,230,000 shares $17.75 million +2.5%4.6%12.3 $14.43 5/31/20231,200,000 shares $13.75 million +0.8%4.5%24.4 $11.46 5/15/20231,190,000 shares $15.23 million +6.3%6.7%26.3 $12.80 4/30/20231,120,000 shares $13.12 million No Change6.7%23.9 $11.71 4/15/20231,120,000 shares $19.32 million No Change6.7%24.2 $17.25 3/31/20231,120,000 shares $16.24 million +0.9%7.0%23.5 $14.50 3/15/20231,110,000 shares $15.11 million +0.9%6.7%21.3 $13.61 2/28/20231,100,000 shares $14.03 million -3.5%6.6%19.4 $12.75 2/15/20231,140,000 shares $12.36 million +0.9%6.9%18.9 $10.84 1/31/20231,130,000 shares $13.73 million -1.7%6.8%19.2 $12.15 1/15/20231,150,000 shares $15.77 million -2.5%6.9%17.2 $13.71 12/30/20221,180,000 shares $15.95 million +4.4%7.1%17.7 $13.52 12/15/20221,130,000 shares $22.83 million -1.7%6.8%17.3 $20.20 11/30/20221,150,000 shares $17.22 million No Change7.0%16.3 $14.97 11/15/20221,150,000 shares $20.65 million +6.5%7.0%17.3 $17.96 10/31/20221,080,000 shares $24.61 million No Change6.5%17.3 $22.79 10/15/20221,080,000 shares $16.75 million No Change6.5%20.1 $15.51 9/30/20221,080,000 shares $17.02 million -0.9%6.5%17.5 $15.76 9/15/20221,090,000 shares $15.74 million -1.8%6.6%12.4 $14.44Biden Nomination CANCELED? (Ad)The Hill just published that Joe Biden has received enough delegates to…“clinch the Democratic presidential nomination and all but guaranteeing he will face off against former President Trump again in November.” Why is he all BUT guaranteed the Democratic nomination, in their words?I believe I have the terrifying answer right here. TRDA Short Interest - Frequently Asked Questions What is Entrada Therapeutics' current short interest? Short interest is the volume of Entrada Therapeutics shares that have been sold short but have not yet been covered or closed out. As of April 30th, traders have sold 1,720,000 shares of TRDA short. 9.54% of Entrada Therapeutics' shares are currently sold short. Learn More on Entrada Therapeutics' current short interest. What is a good short interest ratio for Entrada Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. TRDA shares currently have a short interest ratio of 22.0. Learn More on Entrada Therapeutics's short interest ratio. What is a good short interest percentage for Entrada Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 9.54% of Entrada Therapeutics' floating shares are currently sold short. Is Entrada Therapeutics' short interest increasing or decreasing? Entrada Therapeutics saw a drop in short interest in April. As of April 30th, there was short interest totaling 1,720,000 shares, a drop of 1.7% from the previous total of 1,750,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Entrada Therapeutics' float size? Entrada Therapeutics currently has issued a total of 33,760,000 shares. Some of Entrada Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Entrada Therapeutics currently has a public float of 18,020,000 shares. How does Entrada Therapeutics' short interest compare to its competitors? 9.54% of Entrada Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Entrada Therapeutics: Adlai Nortye Ltd. (0.03%), Lexicon Pharmaceuticals, Inc. (9.52%), Acelyrin, Inc. (13.90%), Oculis Holding AG (0.20%), Corbus Pharmaceuticals Holdings, Inc. (6.84%), Fulcrum Therapeutics, Inc. (4.83%), Theravance Biopharma, Inc. (14.10%), Larimar Therapeutics, Inc. (6.11%), PepGen Inc. (1.66%), Travere Therapeutics, Inc. (16.83%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short Entrada Therapeutics stock? Short selling TRDA is an investing strategy that aims to generate trading profit from Entrada Therapeutics as its price is falling. TRDA shares are trading up $0.04 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Entrada Therapeutics? A short squeeze for Entrada Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of TRDA, which in turn drives the price of the stock up even further. How often is Entrada Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including TRDA, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: Adlai Nortye Short Interest Lexicon Pharmaceuticals Short Interest Acelyrin Short Interest Oculis Short Interest Corbus Pharmaceuticals Short Interest Fulcrum Therapeutics Short Interest Theravance Biopharma Short Interest Larimar Therapeutics Short Interest PepGen Short Interest Travere Therapeutics Short Interest Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:TRDA) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersShocking $16T Elon Musk Crypto LeakCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingUrgent Nvidia WarningAltimetry[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsNext President (Not Trump. Not Biden.)The Freeport Society41 banks launch ‘crypto dollar’Stansberry ResearchMost important medical advance in 100 yearsThe Oxford ClubForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press